PURPOSE: To evaluate the efficacy and toxicity of gemcitabine (2', 2'-difluorodeoxycytidine) plus cisplatin in previously untreated patients with advanced transitional-cell carcinoma. PATIENTS AND METHODS: Thirty-one patients with measurable advanced transitional-cell carcinoma who had received no prior chemotherapy for metastatic disease were scheduled to receive gemcitabine 1,000 mg/m(2) intravenously over 30 minutes on days 1, 8, and 15 and cisplatin 70 mg/m(2) over 1 hour on day 2 of a 28-day cycle. Prior adjuvant or neoadjuvant therapy for locally advanced disease was allowed if this was completed more than 1 year before study entry. RESULTS: There were six complete responses and 10 partial responses in 28 assessable patients, for an overall response rate of 16 of 28 (57%). The response rate on an intent-to-treat basis was 16 of 31 patients (52%). The median survival is 13.2 months, with 18 patients still alive at this time. Toxicity was primarily hematologic, with 12 of 31 patients (39%) having > or = grade 3 granulocytopenia and 17 of 31 (55%) having > or = grade 3 thrombocytopenia. Two patients had febrile neutropenia. All patients required a dose modification of gemcitabine at some point in their therapy; the primary reason was thrombocytopenia and/or neutropenia. CONCLUSION: Gemcitabine plus cisplatin is an active regimen for the treatment of urothelial cancer.
PURPOSE: To evaluate the efficacy and toxicity of gemcitabine (2', 2'-difluorodeoxycytidine) plus cisplatin in previously untreated patients with advanced transitional-cell carcinoma. PATIENTS AND METHODS: Thirty-one patients with measurable advanced transitional-cell carcinoma who had received no prior chemotherapy for metastatic disease were scheduled to receive gemcitabine 1,000 mg/m(2) intravenously over 30 minutes on days 1, 8, and 15 and cisplatin 70 mg/m(2) over 1 hour on day 2 of a 28-day cycle. Prior adjuvant or neoadjuvant therapy for locally advanced disease was allowed if this was completed more than 1 year before study entry. RESULTS: There were six complete responses and 10 partial responses in 28 assessable patients, for an overall response rate of 16 of 28 (57%). The response rate on an intent-to-treat basis was 16 of 31 patients (52%). The median survival is 13.2 months, with 18 patients still alive at this time. Toxicity was primarily hematologic, with 12 of 31 patients (39%) having > or = grade 3 granulocytopenia and 17 of 31 (55%) having > or = grade 3 thrombocytopenia. Two patients had febrile neutropenia. All patients required a dose modification of gemcitabine at some point in their therapy; the primary reason was thrombocytopenia and/or neutropenia. CONCLUSION:Gemcitabine plus cisplatin is an active regimen for the treatment of urothelial cancer.
Authors: J Lehmann; M Retz; G Steiner; P Albers; E Jaeger; A Knuth; C Lippert; M Koser; K Stockamp; C Otto; H Melchior; C Fassmann; C Potratz; T Loch; H G Derigs; T Becker; T Kälble; H-J Piechota; L Hertle; S Weinknecht; L Weissbach; M Al-Mwalad; A Hamza; H Henss; D Brkovic; S Pomer; J Roloff; P Walz; R Muschter; U Tunn; E Winter; P Bub; U Kaldenbach; S Roth; A Brauers; G Jakse; A E Richter; M Wirth; J Hartlapp; H Van Ahlen; M Stöckle Journal: Urologe A Date: 2003-04-02 Impact factor: 0.639
Authors: Jung Yong Hong; Moon Ki Choi; Ji Eun Uhm; Min Jae Park; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Won Seog Kim; Won Ki Kang; Hyun Moo Lee; Han Yong Choi; Hoyeong Lim Journal: Med Oncol Date: 2008-11-06 Impact factor: 3.064